Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer disease and mild cognitive impairment

9 September 2021 - In June 2021, the US FDA granted accelerated approval for aducanumab to treat patients with mild cognitive ...

Read more →

Biden Administration unveils plan to cut prescription drug prices

9 September 2021 - The Department of Health and Human Services plan supports legislation to empower the government to negotiate Medicare ...

Read more →

Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?

3 September 2021 - As Democrats design a way to use the government’s leverage to lower drug prices for seniors, ...

Read more →

Don’t meddle with Medicare to save a budget

25 August 2021 - House Democrats this week approved a $3.5 trillion budget framework that has already passed the Senate.  ...

Read more →

COVID-19 vaccines additional doses: codes & payment

16 August 2021 - The FDA amended the emergency use authorisations for both the Pfizer BioNTech COVID-19 vaccine and the ...

Read more →

Medicare expansion and a lower eligibility age are included in Democrats’ $3.5 trillion budget plan

9 August 2021 - There’s no guarantee that these proposals will make it through the full legislative process. ...

Read more →

Characterisation of the pharmaceutical risk sharing arrangement process in Catalonia

10 August 2021 - Pharmaceutical risk sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines ...

Read more →

G1 Therapeutics granted new technology add-on payment for Cosela (trilaciclib) by CMS

4 August 2021 - G1 Therapeutics today announced that CMS has granted a new technology add-on payment for Cosela (trilaciclib ...

Read more →

Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage

21 July 2021 - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a ...

Read more →

CMS proposes rule to increase price transparency, access to care, safety & health equity

19 July 2021 - The Centers for Medicare & Medicaid Services is proposing actions to address the health equity gap, ...

Read more →

Will CMS find aducanumab reasonable and necessary for Alzheimer disease after FDA approval?

19 July 2021 - The recent US FDA approval of aducanumab for the treatment of Alzheimer disease triggered both praise and ...

Read more →

CMS opens national coverage determination analysis on treatment for Alzheimer’s disease

12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a ...

Read more →

Sanders, progressives face split with centrists over plan to cut drug prices in Medicare

7 July 2021 - Those seeking bipartisan measure say empowering Medicare to negotiate for lower prices could hurt innovation. ...

Read more →

Costco could have saved Medicare $2.6 billion in drug spending, analysis shows

6 July 2021 - Medicare spent billions more money on generic drugs for its beneficiaries than warehouse chain Costco did ...

Read more →

Medicare ‘coverage with evidence development’ for aducanumab? How might it work?

30 June 2021 - In the wake of the FDA’s controversial decision to approve aducanumab for Alzheimer’s disease, how will, and ...

Read more →